Results 141 to 150 of about 67,068 (268)

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

Advanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy, Zoe L. Chau, Sheng‐You Chen, Nanami Fujisawa, John J. Hill, Barnett M. Hsu, Joanne K. Liu, Karol W. Mai, James J. Lai   +8 more
wiley   +1 more source

Comparison of premenstrual symptoms, psychological well-being, and nutritional status between Palestinian women with and without polycystic ovarian syndrome: a case-control study

BMC Women's Health
Background Polycystic ovarian syndrome (PCOS) is a widely seen reproductive and endocrinological disorder. PCOS can exert substantial effects on many aspects of an individual’s life, including reproductive health and psychological well-being.
Marwa Almahareeq, May Hamdan, Divya Vanoh, Nuha Shawarb, Jana Herbawi, Eman Shawar, Raneen Al-wohoush, Manar Mohtaseb, Manal Badrasawi   +8 more
doaj   +1 more source

Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? [PDF]

, 2008
Talbott, EO
core   +1 more source

Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Cancer Medicine, Volume 15, Issue 5, May 2026.
Molecular profiles and outcomes of CR rate in 74 cases. ABSTRACT Objective To investigate the impact of various molecular characteristics on the outcomes of fertility‐preserving therapy in patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH).
Xue‐Qian Qian, Hao‐Hui Fu, Xiao‐Yun Wan, Dong‐Xiao Hu, Yuan‐Ming Shen   +4 more
wiley   +1 more source

Pathogenesis and treatment of obesity-related polycystic ovary syndrome

Journal of Ovarian Research
Polycystic ovary syndrome (PCOS) is a gynecological endocrine disorder affecting 5%–18% of women of reproductive age worldwide. It is characterized by hyperandrogenemia (HA), anovulation, and polycystic ovarian morphology (PCOM), severely impacting women’
Xiaoling Ouyang, Qi Zhou, Hong Tang, Linxia Li   +3 more
doaj   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source

Polycystic Ovary Syndrome (PCOS) [PDF]

Journal of Fertilization: In vitro, 2012
openaire   +1 more source